Phase I evaluation of an epothilone B analog (BMS-247550): clinical findings and molecular correlates

Li Liu, MD

University of Pennsylvania Cancer
Last Modified: May 13, 2001

Presenter: S. Mani
Affiliation: NYU Medical Center, NY

Background:

    The epothilones are naturally occurring antimitotic drugs that share with the taxanes a similar mechanism of action without apparent structural similarity. Some early pre-clinical data demonstrated activity against taxane- sensitive and -resistant tumors,

Materials and Methods:

  • A total of 13 patients with various solid malignancies were included in this phase I study
  • Patients were treated with 1-hour infusion of BMS-247550 once every 3 weeks
  • Five dose levels ranging from 7.4 mg/m2 to 59.2 mg/m2 were evaluated

Results:

  • At dose of 50mg/m2, 50% of patients experienced dose-limiting neutropenia/sepsis
  • Other toxicity include neuropathy, anorexia, and weakness
  • Three patients had subjective responses

Authors' Conclusions

  • The MTD of BMS-247550 was established in this phase I study
  • Clinical response was seen one patient with taxane-refractory breast cancer

Clinical/Scientific Implications:

  • The premominant dose-limiting toxicity of BMS- 247550 is neutropenia
  • Clinical toxicity profile should be validated in large trials
  • The clinical responsiveness will be assessed in phase II trials

ASCO Abstract 269

Saturday | Sunday | Monday | Tuesday

OncoLink ASCO 2001 coverage is provided by an unrestricted educational grant from Amgen

Blogs

Don't Assume You Understand
by Bob Riter
July 29, 2015

Related News

ASCO Updates Guidelines for Hepatitis B Screening in Cancer

May 15, 2015

Screening urged for patients with risk factors for infection, receiving cancer tx linked to reactivation


Obesity, Overweight at Diagnosis Ups B-Cell Lymphoma Prognosis

May 30, 2012

Improved survival for U.S. vets who are overweight, obese at diagnosis of diffuse large B-cell lymphoma


ASCO: Anti-PD-1 Antibody Active Against Various Cancers

Jun 5, 2012

Immunotherapy with BMS-936558 has antitumor activity in melanoma, NSCLC, renal cell cancer